Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 502 Results

Page 12 of 51« First «...10 111213 14...20 30 40...»Last »

May 9, 2023

DBV Technologies to Participate in Upcoming Investor Conference

May 4, 2023

DBV Technologies Reports First Quarter 2023 Financial Results

April 19, 2023

DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA

April 12, 2023

DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

March 24, 2023

Ordinary and Extraordinary General Meeting of April 12, 2023

March 13, 2023

DBV Technologies Update

March 7, 2023

DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old

March 2, 2023

DBV Technologies Reports Full Year 2022 Financial Results and Business Update

March 2, 2023

DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document

February 27, 2023

DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023

Page 12 of 51« First «...10 111213 14...20 30 40...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Cookies Policy

Scroll to Top